Vietnam pharma 2027 outlook: generics localization and biosimilar adoption
Vietnam's pharma market enters 2027 anchored on a USD 8.0 bn 2025 base trending to USD 12.0 bn by 2030. Decision 1165 sets the domestic-supply policy floor at 80% volume / 70% value by 2030, and Circular 40/2025/TT-BYT now rewards EU-GMP-certified local production in hospital tenders. The biosimilar wave — Celltrion's Remsima and Herzuma already launched; Nanogen's Stimus in late-stage trials — opens the second margin leg.
Executive summary
Vietnam's pharmaceutical market is valued at approximately $7.5 billion in 2025, growing at 11% CAGR driven by ageing demographics, rising chronic disease prevalence, expanding National Health Insurance (BHYT) coverage (currently 93% of population), and increasing healthcare spending as incomes rise. Domestic pharmaceutical manufacturers — Dược Hậu Giang, Imexpharm, Pymepharco — supply approximately 50% of the market by volume but primarily in generic formulations and OTC products. Imported branded pharmaceuticals from Europe, US, Japan, and Korea dominate the hospital tender and high-value prescription segments. Vietnam's pharmaceutical regulatory authority (DAV) is implementing WHO-GMP certification requirements that are driving consolidation among domestic manufacturers and attracting FDI in compliant manufacturing. This report covers Vietnam's pharmaceutical market by segment and distribution channel, BHYT reimbursement dynamics, domestic versus imported brand dynamics, regulatory modernisation timeline, hospital tender market structure, and the market growth outlook through 2027.
Report details
- Published
- 2026-05-26
- Pages
- 26
- Format
- Code
- VN-PHA-XPL-D27-01
- Market
- Vietnam
- Industry
- Pharma
- Year
- 2026
Table of contents · 11 sections
- 01 Methodology
- 02 Contents
- 03 Executive summary
- 04 Macro & policy backbone
- 05 Market sizing & channel split
- 06 Localization & the EU-GMP race
- 07 Competitive landscape
- 08 Biosimilar adoption
- 09 Regulatory & tender system
- 10 5-year outlook & forecast
- 11 Methodology endnote
The full report is available to subscribers and buyers. The executive summary above is free to read.